Cost-Effectiveness of the Addition of Rituximab to CHOP Chemotherapy in First-Line Treatment for Diffuse Large B-Cell Lymphoma in a Population-Based Observational Cohort in British Columbia, Canada
Authors:
- Carlo A. MarraCMCarlo A. Marra
- Joseph M. ConnorsJCJoseph M. Connors
- Mehdi NajafzadehMNMehdi Najafzadeh
- Laurie SehnLSLaurie Sehn
- Stuart J. PeacockStuart J. Peacock
- 1 September 2010
- journal article
- Published by Elsevier in Value in Health
- Vol. 13 (6) , 703-711
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British ColumbiaJournal of Clinical Oncology, 2005
- Cost-Effectiveness Analysis of Rituximab Combined with CHOP for Treatment of Diffuse Large B-Cell LymphomaValue in Health, 2005
- Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B‐cell lymphomaCancer, 2005
- Cost‐effectiveness of rituximab (MabThera®) in diffuse large B‐cell lymphoma in the NetherlandsEuropean Journal of Haematology, 2005
- Rituximab (MabThera®) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluationHealth Technology Assessment, 2004
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- A Systematic Overview of Chemotherapy Effects in Aggressive non-Hodgkin's LymphomaActa Oncologica, 2001
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998
- Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- ADVANCED DIFFUSE HISTIOCYTIC LYMPHOMA, A POTENTIALLY CURABLE DISEASEThe Lancet, 1975